Clinical trials · Houston, TX
Leukemia clinical trials in Houston
We’re tracking 183 recruiting leukemia studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Houston, TexasAges 12 years+ - NCT01853631RecruitingPhase 1
CAR T-cell therapy for CD19-positive B-cell blood cancers
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
Houston, TexasAges Up to 75 years - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Houston, TexasAges 18 years+ - NCT06345027RecruitingPhase 1
CAR T cell therapy targeting CD70 for leukemia
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
Houston, TexasAges Up to 75 years - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Houston, TexasAges 18 years+ - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Houston, TexasAges Up to 39 years - NCT02390635RecruitingPhase 1
Testing PET/MRI scans to find leukemia outside the bone marrow
This Phase 1 study uses special whole-body imaging scans (PET with CT, plus MRI) to look for signs of acute myeloid leukemia outside the bone marrow. It may help doctors better see where leukemia is and guide future care.
Houston, TexasAges 18 years+ - NCT05010772RecruitingPhase 1
Maintenance treatment study for AML in remission
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT06236724RecruitingPhase 2
Asciminib for newly diagnosed chronic myeloid leukemia
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Houston, TexasAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT05010122RecruitingPhase 1/Phase 2
Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Houston, TexasAges 18 years+ - NCT04953910RecruitingPhase 1
Oral decitabine for cancers with liver problems
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Houston, TexasAges 18 years+ - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Houston, TexasAges Up to 1 year - NCT06229912RecruitingPhase 2
Revumenib for leukemia with HOX gene changes
This trial tests an oral drug called revumenib (a menin inhibitor) for patients with acute leukemia that has returned or not responded to treatment, and whose leukemia has a specific HOX gene change. Revumenib aims to stop cancer growth by blocking a protein that helps leukemia cells survive.
Houston, TexasAges 12 years+ - NCT05011045Recruiting
Brain radiation study tracking thinking and memory changes
This study looks at how whole-brain radiation affects thinking, memory, and other brain function in people with blood cancers that involve the brain. It may help doctors understand what to expect and which supportive treatments or monitoring could be useful.
Houston, TexasAges 18 years+ - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Houston, TexasAges 18 years+ - NCT06235801RecruitingPhase 1/Phase 2
Combination targeted therapy for relapsed FLT3-mutated leukemia
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
Houston, TexasAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Houston, TexasAges 18 years+ - NCT01409161RecruitingPhase 2
Tretinoin and arsenic drugs for newly diagnosed acute promyelocytic leukemia
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
Houston, TexasAges 10 years+ - NCT03263572RecruitingPhase 2
Study medicines for Philadelphia-positive ALL or relapsed leukemia
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Houston, TexasAges 18 years+ - NCT00412594RecruitingPhase 2
Cladribine plus rituximab for hairy cell leukemia
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
Houston, TexasAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Houston, TexasAges Any age - NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
Houston, TexasAges 4 weeks–21 years
Hear when a new Leukemia trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
Leukemia trials in other cities
Where these studies are running near Houston
Institutions with a site for the recruiting leukemia studies listed above.
- The University of Texas MD Anderson Cancer Center · 18 studies
- Texas Children's Hospital · 3 studies
- MD Anderson Cancer Center · 2 studies
- Baylor College of Medicine
- Ben Taub General Hospital
- Houston Methodist Hospital
- MD Anderson Regional Care Center-Bay Area
- MD Anderson Regional Care Center-Katy
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting leukemia studies in Texas.
Common questions
- Are there leukemia clinical trials near Houston?
- Yes. We're currently tracking 183 recruiting leukemia studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.